RAPID RESPONSE

In clinical trials with CIMZIA, a majority of patients experienced a significant reduction of the signs and symptoms of RA and significant inhibition of structural damage at weeks 24 and 52, with some patients experiencing a reduction in symptoms within 1 to 2 weeks.^1,2

In the 52-week RAPID 1 pivotal clinical trial with CIMZIA, a co-primary end point was ACR20 response rate at week 24 (59% vs 14% for placebo).¹ Significant ACR20 response to CIMZIA was seen as early as 1 to 2 weeks in some patients, peaking at week 12 in 64% of patients.^1,2

Indication
CIMZIA is indicated for the treatment of adults with moderate to severe rheumatoid arthritis (RA).

Important Safety Information
Serious and sometimes fatal side effects have been reported with CIMZIA, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens (such as Legionella or Listeria). Patients should be closely monitored for the signs and symptoms of infection during and after treatment with CIMZIA. Lymphoma and other malignancies also have been reported in children and adolescents. CIMZIA is not indicated for use in pediatric patients.

*The CIMZIA Co-pay Savings Card program is valid for out-of-pocket expenses for CIMZIA for up to 17 uses. The CIMZIA Co-pay Savings Card program is not valid for prescriptions that are reimbursed, in whole or part, under Medicare (including Medicare Part D), Medicaid, similar federal or state funded programs (including any state prescription drug assistance programs and the Government Health Insurance Plan available in Puerto Rico), private insurance in the Commonwealth of Massachusetts, or where otherwise prohibited by law. Product dispensed pursuant to program rules and federal and state laws. Claims should not be submitted to any public payor (i.e., Medicare, Medicaid, Medigap, Tricare, VA and DoD) for reimbursement. The parties reserve the right to amend or end this program at any time without notice.

medication guide & prescribing information

important safety information regarding fungal infections

For more information 1-866-4-CIMZIA (1-866-424-6942)

References:

1. Keystone E, Heijde D, Mason D Jr, et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 2008;58(11):3319-3329.
2. Data on file. UCB, Inc.; Smyrna, GA.
3. Aletaha D, Funovits J, Keystone E, Smolen JS. Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. Arthritis Rheum. 2007;56(10):3226-3235.
4. CIMZIA [prescribing information]. Smyrna, GA: UCB, Inc.; 2011.